Cabaletta Bio (CABA) Stock Forecast, Price Target & Predictions
CABA Stock Forecast
Cabaletta Bio stock forecast is as follows: an average price target of $16.33 (represents a 284.24% upside from CABA’s last price of $4.25) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CABA Price Target
The average price target for Cabaletta Bio (CABA) is $16.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $3.00. This represents a potential 284.24% upside from CABA's last price of $4.25.
CABA Analyst Ratings
According to 5 Wall Street analysts, Cabaletta Bio's rating consensus is 'Buy'. The analyst rating breakdown for CABA stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cabaletta Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Ben Burnett | Stifel Nicolaus | $32.00 | $17.54 | 82.44% | 652.94% |
| Jan 03, 2023 | - | Wells Fargo | $14.00 | $9.30 | 50.54% | 229.41% |
| Aug 30, 2022 | Michael Ulz | Morgan Stanley | $3.00 | $1.25 | 139.04% | -29.41% |
The latest Cabaletta Bio stock forecast, released on Mar 21, 2024 by Ben Burnett from Stifel Nicolaus, set a price target of $32.00, which represents a 82.44% increase from the stock price at the time of the forecast ($17.54), and a 652.94% increase from CABA last price ($4.25).
Cabaletta Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $32.00 |
| Last Closing Price | $4.25 | $4.25 | $4.25 |
| Upside/Downside | -100.00% | -100.00% | 652.94% |
In the current month, the average price target of Cabaletta Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cabaletta Bio's last price of $4.25. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 29, 2024 | Citigroup | Buy | Buy | Hold |
| Apr 04, 2024 | Citigroup | Buy | Buy | Hold |
| Nov 15, 2023 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jul 18, 2023 | Guggenheim | - | Buy | Initialise |
| Jan 03, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Sep 14, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 30, 2022 | Morgan Stanley | - | Overweight | Downgrade |
Cabaletta Bio's last stock rating was published by Citigroup on Apr 29, 2024. The company gave CABA a "Buy" rating, the same as its previous rate.
Cabaletta Bio Financial Forecast
Cabaletta Bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Cabaletta Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CABA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Cabaletta Bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict CABA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cabaletta Bio's previous annual EBITDA (undefined) of $NaN.
Cabaletta Bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-41.90M | $-40.86M | $-40.18M | $-38.27M | $-34.94M | $-36.59M | $-34.86M | $-33.13M | $-29.75M | $-29.44M | $-27.08M |
| High Forecast | $-41.90M | $-40.86M | $-40.18M | $-38.27M | $-34.94M | $-36.59M | $-34.86M | $-33.13M | $-29.75M | $-23.13M | $-27.08M |
| Low Forecast | $-41.90M | $-40.86M | $-40.18M | $-38.27M | $-34.94M | $-36.59M | $-34.86M | $-33.13M | $-29.75M | $-33.64M | $-27.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Cabaletta Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CABA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cabaletta Bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Cabaletta Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CABA last annual SG&A of $NaN (undefined).
Cabaletta Bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.85 | $-0.83 | $-0.81 | $-0.77 | $-0.71 | $-0.74 | $-0.70 | $-0.67 | $-0.60 | $-0.60 | $-0.55 |
| High Forecast | $-0.85 | $-0.83 | $-0.81 | $-0.77 | $-0.71 | $-0.74 | $-0.70 | $-0.67 | $-0.60 | $-0.47 | $-0.55 |
| Low Forecast | $-0.85 | $-0.83 | $-0.81 | $-0.77 | $-0.71 | $-0.74 | $-0.70 | $-0.67 | $-0.60 | $-0.68 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Cabaletta Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CABA previous annual EPS of $NaN (undefined).
Cabaletta Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| CABA | Cabaletta Bio | $4.26 | $16.33 | 283.33% | Buy |
| PLRX | Pliant Therapeutics | $12.87 | $40.50 | 214.69% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| ETNB | 89bio | $8.47 | $22.00 | 159.74% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| LRMR | Larimar Therapeutics | $8.05 | $14.50 | 80.12% | Buy |
| MDGL | Madrigal Pharmaceuticals | $243.89 | $315.75 | 29.46% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
CABA Forecast FAQ
Is Cabaletta Bio a good buy?
Yes, according to 5 Wall Street analysts, Cabaletta Bio (CABA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of CABA's total ratings.
What is CABA's price target?
Cabaletta Bio (CABA) average price target is $16.33 with a range of $3 to $32, implying a 284.24% from its last price of $4.25. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cabaletta Bio stock go up soon?
According to Wall Street analysts' prediction for CABA stock, the company can go up by 284.24% (from the last price of $4.25 to the average price target of $16.33), up by 652.94% based on the highest stock price target, and down by -29.41% based on the lowest stock price target.
Can Cabaletta Bio stock reach $6?
CABA's average twelve months analyst stock price target of $16.33 supports the claim that Cabaletta Bio can reach $6 in the near future.
What are Cabaletta Bio's analysts' financial forecasts?
Cabaletta Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-140M (high $-140M, low $-140M), average SG&A $0 (high $0, low $0), and average EPS is $-2.822 (high $-2.822, low $-2.822). CABA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-161M (high $-161M, low $-161M), average SG&A $0 (high $0, low $0), and average EPS is $-3.26 (high $-3.26, low $-3.26).